Summary
Heparin is a complex polysaccharide, consisting of repeating dissacharide subunits, which exerts its anticoagulant effect by potentiating the inhibition of activated clotting proteins by the naturally occurring inhibitor antithrombin III. The primary indication for its use is venous thromboembolic disease where an average 20,000 to 40,000 USP units are initially administered by constant infusion over 24 hours to prevent extension of an established thrombus. Subsequent treatment is based on the therapeutic response, usually monitored by a global clotting test such as the activated partial thromboplastin time (APTT). The chromogenic assay based on heparin-induced inhibition of activated factor X (Xa) is a particularly useful alternative monitoring test where thrombosis complicates pregnancy or is associated with the lupus anticoagulant.
Subcutaneous heparin has also been used for the primary treatment of venous thrombosis but is more frequently used either for primary or secondary prophylaxis. Primary prophylaxis schedules usually employ a low dose (5000 units) administered 8- or 12-hourly without anticoagulant control, but a titrated subcutaneous heparin regimen has been successfully reported in elective hip surgery.
Although arterial thrombosis is primarily initiated by platelet aggregates forming in vivo, heparin is commonly administered for acute arterial thromboembolism including peripheral arterial occlusion and repeated transient cerebral ischaemic events. The potential efficacy of heparin in disseminated intravascular consumption (DIC) remains to be firmly established, but is indicated where symptomatic thrombotic complications occur.
Thrombocytopenia and haemorrhagic side effects may complicate heparin therapy, but bleeding complications may be minimised with the development of modified low molecular weight heparin which is currently undergoing clinical trial.
Similar content being viewed by others
References
Andersson, G. et al.: Subcutaneous administration of heparin. A randomised comparison with intravenous administration of heparin to patients with deep vein thrombosis. Thrombosis Research 27: 631 (1982).
Arnesen, H. et al.: A prospective study of streptokinase and heparin in the treatment of deep vein thrombosis. Acta Medica Scandinavica 203: 457 (1978).
Basu, D. et al.: A prospective study of the value of monitoring heparin therapy with the activated partial thromboplastin time. New England Journal of Medicine 287: 324 (1972).
Bounameaux, H. et al.: Monitoring of heparin time. American Journal of Clinical Pathology 74: 68 (1980).
Brucke, P. et al.: Prophylaxis of post-operative thromboembolism: Low dose heparin versus heparin plus dihydroergotamine. Thrombosis Research 29: 377 (1983).
Cerebral Embolism Study Group. Immediate anticoagulation of embolic stroke: A randomised trial. Stroke 14: 668 (1983).
Cerebral Embolism Study Group. Immediate anticoagulation of embolic stroke: Brain haemorrhage and management options. Stroke 15: 779 (1984).
Gallus, A.S. et al.: Small subcutaneous doses of heparin in the prevention of venous thrombosis. New England Journal of Medicine 288: 545 (1973).
Gallus, A. et al.: The optimal duration of initial heparin treatment for venous thromboembolism. Thrombosis and Haemostasis 50: 52 (1983).
Hampson, W.G. et al.: Failure of low dose heparin to prevent deep vein thrombosis after hip replacement arthroplasty. Lancet 2: 795 (1974).
Hellgren, M. et al.: Pregnancy in women with congenital antithrombin III deficiency: Experience of treatment with heparin and antithrombin. Gynecologic and Obstetric Investigations 14: 127 (1982).
Hull, R. et al.: Warfarin sodium versus low dose heparin in the longterm treatment of venous thrombosis. New England Journal of Medicine 301: 855 (1979).
Hull, R. et al.: Adjusted subcutaneous heparin versus warfarin sodium in the longterm treatment of venous thrombosis. New England Journal of Medicine 306: 189 (1982).
Jacobs, J. et al.: Intravenous infusions of heparin and penicillins. Journal of Clinical Pathology 26: 742 (1973).
Kakkar, V.V. et al.: Prophylaxis for postoperative deep vein thrombosis. Synergistic effect of heparin and dihydroergotamine. Journal of the American Medical Association 241: 39 (1979).
Kakkar, V.V. et al.: Low molecular weight heparin and prevention of postoperative deep vein thrombosis. British Medical Journal 284: 375 (1982).
Katzen, B.T. and van Breda, A.: Low dose streptokinase in the treatment of arterial occlusions. AJR 136: 1171 (1981).
Letsky, E.A. and de Swiet, M.: Thromboembolism in pregnancy and its management. British Journal of Haematology 57: 543 (1984).
Leyfraz, P.F. et al.: Adjusted versus fixed dose subcutaneous heparin in the prevention of deep vein thrombosis after total hip replacement. New England Journal of Medicine 309: 954 (1983).
Marciniak, E. and Gockerman, J.P.: Heparin induced decrease in circulating antithrombin III. Lancet 2: 581 (1977).
McCarthy, S.J. et al.: Low dose heparin as a prophylaxis against deep vein thrombosis after acute stroke. Lancet 2: 800 (1977).
Nicolaides, A.N. et al.: Small doses of subcutaneous sodium heparin in preventing deep thrombosis after major surgery. Lancet 2: 890 (1972).
Rosenberg, R.D.: Heparin, antithrombin and abnormal clotting. Annual Review of Medicine 29: 367 (1978).
Sack, G.H. et al.: Trousseau’s syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasia. Clinical pathologic and therapeutic features. Medicine 56: 1 (1977).
Sasahara, A.A. et al.: A Multicenter Trial. Dihydroergotamine — heparin prophylaxis of post-operative deep vein thrombosis. Journal of the American Medical Association 251: 2960 (1984).
Shields, R.W. et al.: Anticoagulant related haemorrhage in acute cerebral embolism. Stroke 15: 426 (1984).
Veterans’ Administration Cooperative Trial. Anticoagulants in acute myocardial infarction. Journal of the American Medical Association 225: 725 (1973).
Warlow, C. et al.: A double blind randomised trial of low doses of subcutaneous heparin in the prevention of deep vein thrombosis after myocardial infarction. Lancet 2: 934 (1973).
Weksler, B.B. and Lewin, M.: Anticoagulation in cerebral ischaemia. Stroke 14: 658 (1983).
Wilson, J.E. et al.: Heparin therapy in venous thromboembolism. American Journal of Medicine 70: 808 (1981).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ockelford, P. Heparin 1986. Drugs 31, 81–92 (1986). https://doi.org/10.2165/00003495-198631010-00007
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-198631010-00007